Cetuximab-based chemotherapy, specifically targeting EGFR, is a mainstay treatment for HNSCC, but few patients benefit from it because of intrinsic resistance or acquired resistance after prolonged treatment [40,41,42,43]. The gene discussed is EGFR; the disease is head and neck squamous cell carcinoma.